Moreover, the weight of tumours in the AZD5438 treated mice cohort was in general 60% less than in vehicle treated mice (p < 0.01, t-test) (Fig 8C), suggesting that AZD5438 could inhibit a KRAS mutant tumour in vivo. The gene discussed is KRAS; the disease is neoplasm.